Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2013

01-06-2013 | Letter to the Editor

“Combined” small cell and “pure” small cell lung cancer: is there a clinical difference?

Authors: Young Hak Kim, Michiaki Mishima, Hiroshi Date

Published in: Medical Oncology | Issue 2/2013

Login to get access

Excerpt

To the Editor, …
Literature
1.
Travis WD, Coby TV, Corrin B, et al. World Health Organization international histological classification of tumors. 3rd ed. Berlin: Springer; 1999.
2.
Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–97.PubMedCrossRef
3.
Adelstein DJ, Tomashefski JF Jr, Snow NJ, et al. Mixed small cell and non-small cell lung cancer. Chest. 1986;89:699–704.PubMedCrossRef
4.
Mangum MD, Greco FA, Hainsworth JD, et al. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12.PubMed
5.
Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 2007;98:1714–9.PubMedCrossRef
Metadata
Title
“Combined” small cell and “pure” small cell lung cancer: is there a clinical difference?
Authors
Young Hak Kim
Michiaki Mishima
Hiroshi Date
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0600-1

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue

Original Paper

Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients

Original Paper

Polymorphic CT dinucleotide repeat in the GATA3 gene and risk of breast cancer in Iranian women

Original Paper

Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center

Review Article

Primary CNS germ cell tumors: current epidemiology and update on treatment

Original Paper

Hypermethylation and prognostic implication of Syk gene in human colorectal cancer

Review Article

Integrating complementary medicine in supportive cancer care models across four continents
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits